A 52-year-old morbidly obese man with chronic obstructive pulmonary disease complains of shortness of breath at rest and dyspnea on exertion.
In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.
Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.
Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD
Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.
The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.
The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.
Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.
Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.
Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.
Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.
In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.
In patients with diabetes who had an acute myocardial infarction, the acute-to-chronic glycemic ratio was a better predictor of mortality compared with baseline glycemia levels.
The expanded use of TIMI Risk Score for Secondary Prevention in patients with T2D may be helpful to predict risk for CV events accurately.
Renin-independent aldosteronism, and possibly mineralocorticoid receptor activation increase risk for hypertension.
Glucagon-like peptide-1 receptor agonists can reduce major adverse cardiovascular events in patients with type 2 diabetes.
Patients with visit-to-visit variability of fasting plasma glucose may have a higher risk of developing cardiovascular disease and all-cause mortality.
The FDA has approved semaglutide injection for the treatment of type 2 diabetes in adults.
Weight gain associated with insulin therapy is not associated with adverse cardiovascular outcomes in people with type 2 diabetes.
The study investigates the correlation between hypoglycemia and the risk for all-cause mortality in patients with type 2 diabetes.
Patients with chronic heart failure and diabetes may have a greater reduction in mortality with higher beta-blocker doses.
Obesity, hypertension, and circadian misalignment may all result from sleep debt.
The Cardiology Advisor Articles
- A 45-Year-Old Man Presents to the ED With Shortness of Breath, Confusion
- A 56-Year-Old Man With Flu-Like Symptoms Presents With Palpitations
- Acute Coronary Syndrome Benefits From Both Antiplatelets and DOACs
- 6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH
- Fear of E-Cigarette Harm Cuts Teenagers' Use
- Clopidogrel Tablets Recalled Due to Mislabeling
- Mandatory Screening for Congenital Heart Disease: Effects on Infant Mortality
- Short-Run Atrial Tachyarrhythmia Associated With Increased Stroke Risk
- Effects of High-Intensity Exercise Training in Previously Sedentary Adults
- ACC Releases Decision Pathway on Heart Failure With Reduced Ejection Fraction
- Clinical Challenge: Upper Respiratory Infection 1 Year After Heart Transplant
- Use of Multiple Antihypertensive Agents Has Increased in Hospitalizations Complicated by Preeclampsia
- Targeting Underlying Conditions May Improve Sinus Rhythm in Atrial Fibrillation
- Metformin May Preserve Beta-Cell Function in T2DM
- A 67-Year-Old Man With Shortness of Breath After the Sonoma-Napa Wildfires